Case Studies / Rapid clinical evidence summary for landmark CVOT: fiel…
Medical Affairs Evidence Generation Cardiology

Rapid clinical evidence summary for landmark cardiovascular outcomes trial (CVOT): field-ready within 72 hours of publication

Challenge
A landmark CVOT publication would be widely discussed at the next round of KOL meetings. MSL teams needed a field-ready briefing before cardiologists had time to form their own independent interpretation.
Approach
Pre-planned rapid response protocol triggered at publication. Clinical summary, brand-contextualised MSL talking points, and anticipated cardiologist questions assembled and approved within 72 hours.
Result
All field teams received the summary within 72 hours of publication — before the next scheduled KOL meeting cycle.
The challenge

Publication day is a scientific event and a competitive event simultaneously

Cardiovascular outcomes trials are high-visibility scientific events. When a major CVOT publishes, cardiologists read the New England Journal of Medicine before their MSL team has been briefed. Within 48 hours of publication, the trial's findings are being discussed at cardiology grand rounds, department meetings, and informal conversations between clinicians.

For a brand with a cardiovascular product in the same class, this window is critical. If the MSL team cannot engage meaningfully with the new data in those first conversations, they cede the scientific narrative to their cardiologist customers — who will interpret the data without the brand's contextual framing.

The brand had a standard congress response protocol, but a landmark publication required a different kind of response — faster, more targeted, and calibrated specifically for the field conversation context rather than the academic review context.

Your cardiologists will read the NEJM paper on Sunday. Your MSLs need to be ready to discuss it with them on Monday. The window between publication and the first KOL conversation is where the scientific narrative is shaped.

Our approach

What we did

1
Pre-publication preparation
Three weeks before the expected publication date, prepared a response framework: identified the likely key findings from trial registration data, drafted provisional talking points, and prepared a template for rapid completion once the full paper was available.
2
Rapid data review at publication
Within 4 hours of publication, conducted a structured scientific review of the full paper and supplementary data. Identified the 5 primary data points most relevant to the brand's evidence position.
3
Contextualised MSL briefing
Drafted a 4-page MSL field briefing: clinical summary of the trial, brand-contextualised interpretation, head-to-head comparisons where data allowed, and 12 anticipated physician questions with suggested responses.
4
Medical review and approval
Submitted to Medical Director for review within 24 hours. One review cycle, using a pre-agreed streamlined approval process for time-sensitive publications.
5
Distribution and follow-up
Distributed to all field teams with a structured briefing call option. Prepared a second-wave FAQ 48 hours later based on field queries received after initial distribution.
Result

Measurable impact

The clinical summary, MSL talking points, and FAQ were distributed to all field teams 68 hours after publication — within the 72-hour target. MSL teams entering scheduled KOL meetings that week were fully briefed. Post-distribution feedback from field medical directors indicated that cardiologists in multiple markets were receptive to the brand's contextual framing of the new data. The pre-publication preparation model was adopted as standard practice for all future high-priority publication monitoring.

68 hours
From publication to complete field team distribution
12
Anticipated physician questions addressed in initial briefing
1 review cycle
Streamlined approval enabling speed without sacrificing accuracy
Facing a similar challenge?

Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.

Evidence Scanner
Evidence ScannerTM
AI infrastructure

AI-powered.
Expert-validated.

We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.

Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Electronic data capture with AI-assisted structuring of unstructured records
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
Evidence Scanner · Research module
// Query: ribociclib OS data MONALEESA 2023–24
search("ribociclib overall survival", {
  years: [2023, 2024],
  output: "structured_table"
})
// 847 records → 23 relevant
Processing 847 records...
Evidence Summary
MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...